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REPORT
Heterozygous De Novo UBTF Gain-of-Function Variant
Is Associated with Neurodegeneration in Childhood
Simon Edvardson,1,2,15 Claudia M. Nicolae,3,15 Pankaj B. Agrawal,4 Cyril Mignot,5 Katelyn Payne,6
Asuri Narayan Prasad,7 Chitra Prasad,8 Laurie Sadler,9 Caroline Nava,5,10 Thomas E. Mullen,11,12
Amber Begtrup,13 Berivan Baskin,13 Zo¨e Powis,14 Avraham Shaag,1 Boris Keren,5
George-Lucian Moldovan,3,* and Orly Elpeleg1,*
Summary
Ribosomal RNA (rRNA) is transcribed from rDNA by RNA polymerase I (Pol I) to produce the 45S precursor of the 28S, 5.8S, and 18S rRNA
components of the ribosome. Two transcription factors have been defined for Pol I in mammals, the selectivity factor SL1, and the
upstream binding transcription factor (UBF), which interacts with the upstream control element to facilitate the assembly of the tran-
scription initiation complex including SL1 and Pol I. In seven unrelated affected individuals, all suffering from developmental regression
starting at 2.5–7 years, we identified a heterozygous variant, c.628G>A in UBTF, encoding p.Glu210Lys in UBF, which occurred de novo
in all cases. While the levels of UBF, Ser388 phosphorylated UBF, and other Pol I-related components (POLR1E, TAF1A, and TAF1C)
remained unchanged in cells of an affected individual, the variant conferred gain of function to UBF, manifesting bymarkedly increased
UBF binding to the rDNA promoter and to the 50- external transcribed spacer. This was associated with significantly increased 18S expres-
sion, and enlarged nucleoli which were reduced in number per cell. The data link neurodegeneration in childhood with altered rDNA
chromatin status and rRNA metabolism.
Neurodegenerative disorders that present in childhood are
a group of heterogeneous conditions with a genetic basis
that lead to a progressive decline in psychomotor function.
The primary target in these disorders might involve any of
the structural components of the nervous system (neurons
and their projections, and supportive elements; astrocytes
and glial cells). Earlier concepts considered neurodegener-
ative disorders as affecting the ‘‘greymatter’’ (e.g., neuronal
ceroid lipofuscinosis [MIM 256730], Rett syndrome [MIM
312750]) or ‘‘white matter’’ (e.g., Krabbe Leukodystrophy
[MIM 245200]) disorders. Advances in genomic medicine
have begun to unravel the underlying causes for several
of these conditions, it is clear that a number of cellular
organelles and pathways are involved as targets for patho-
genic mutations eventually leading to a degenerating neu-
ral network.
In childhood, these disorders present with develop-
mental regression (loss of developmental milestones)
affecting multiple domains (motor, social, cognitive)
with or without the presence of seizures.1 Diagnostic delin-
eation rests on the age of onset, deviations in head circum-
ference (microcephaly, macrocephaly) findings on brain
imaging (regional distribution of loss of gray or white
matter (atrophy), and associated signal abnormalities
that might involve the cortex, subcortical gray matter,
and the white matter. In late stages of these disorders,
the distinction between gray and white matter involve-
ment is often blurred.2
The affected individuals, 6 females and 1 male, 8–23
years of age, originated from seven unrelated families; their
clinical and radiologic data are presented in Table 1. In 6/7,
the pregnancy was uneventful, whereas in one, gestational
diabetes and polyhydramnios were reported. The delivery
was uncomplicated in 6/7; one affected individual had
C-section for failed induction and fetal distress. Six/7
were born at term, and one was born at 33 weeks of gesta-
tion. The perinatal course was uneventful and the initial
psychomotor development was reported normal in 4/7
affected individuals; three affected individuals had mild
developmental delay till 2 years of age. Developmental
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regression invariably occurred at 2.5–7 years and in
5 affected individuals was initially confined to motor
domains with a gradual loss of ambulation, fine motor
abilities, self-care skills, and ultimately feeding difficulties
leading to failure to thrive. Within 1–3 years of regression
onset, this was followed by obvious language regression
and the appearance of an extrapyramidal movement disor-
der, which consisted of dystonia, chorea, parkinsonism, or
rigidity. Pyramidal signs and ataxia were present in 4 and 3
affected individuals, respectively, but were not prominent.
Two affected individuals had initial cognitive/language
regression, which was followed by motor regression
though eventually leading to the same endpoint of severe
to profound intellectual disability and inability to ambu-
late. Focal and generalized seizures were reported for
3 affected individuals and one further affected individual
had an abnormal EEG. Head circumference percentiles,
normal at birth, declined over time. No other systems
were involved in particular there was no evidence of dys-
morphism (Figure 1), organomegaly, and hearing or visual
impairment. No hematological or skeletal abnormalities
were present. At the time of writing all the affected individ-
uals were alive.
Numerous routine diagnostic laboratory tests were per-
formed without any specific abnormalities noted. Brain
MRI revealed a non-specific pattern of diffuse cortical atro-
phy and T2 hyperintensity that was either localized to the
periventricular white matter or more extensively affected
the entire subcortical white matter in affected individuals.
This was accompanied by cerebellar atrophy in 5 affected
individuals. In affected individuals where sequential imag-
ing was available, cortical atrophy was noted initially and
appeared to precede the development of cerebellar atrophy
(Figure 2). These findings are frequently encountered in in-
herited pediatric neurodegenerative disorders that primar-
ily affect the gray matter (mitochondrial disorders, Menkes
disease [MIM 309400], Niemann Pick disease type C [MIM
257220], etc.), and therefore would not be considered as
specific to this condition.
For affected individuals 1 and 2 and their parents, WES
was performed on exon targets captured using the Clinical
Research Exome kit (Agilent Technologies, Santa Clara,
CA). The full sequencing methodology and variant inter-
pretation protocol has been previously described.3 The
general assertion criteria for variant classification are
publicly available on the GeneDx ClinVar submission
page. For affected individual 3 and her parents WES was
performed at the Broad Institute of Harvard and MIT
(Cambridge, MA, USA) as described previously.4 WES of
affected individual 4 and her parents was performed on
exon targets captured using Roche SeqCap EZ MedExome.
Sequencing was performed on NextSeq 500. Variant inter-
pretation protocol has been previously described.5 WES
of affected individual 5 and her parents and affected
individual 6 was performed on exon targets captured
using SureSelect Human All Exon 50 Mb Kit V.4 (Agilent
Technologies, Santa Clara, CA, USA). Sequences wereTa
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determined by HiSeq2000 (Illumina, San Diego, CA, USA).
The full sequencing methodology and variant interpreta-
tion protocol were previously described.5 Clinical exome
sequencing of affected individual 7 and her parents was
performed at Ambry Genetics as previously described.6
All the procedures were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national); proper informed
consent was obtained from all guardians.
In the WES of affected individuals 1–5 and 7, following
reads alignment, variant calling, and filtration, all re-
maining variants were heterozygous, and all but one
were inherited from the parents. This was Hg19.Chr17:
42290219G>A, NM_014233.3:c.628G>A, p.Glu210Lys in
UBTF [MIM 600673]. We verified the finding by Sanger
sequencing in the affected individuals (Figure S1), and
confirmed its absence from the DNA of all the parents
and the healthy sibs. The variant was not carried by any
of the 140,000 individuals whose exome analyses were
deposited at gnomAD but was carried by one of the
affected individuals at the Hadassah WES database (2,100
exome analyses). This was affected individual 6 and the
variant was confirmed de novo by Sanger sequencing.
UBTF encodes the 764 amino acids of UBF, which is a
Pol I transcription factor and is instrumental in the gener-
ation of rRNA transcripts. The biogenesis of ribosome com-
ponents is a delicate and balanced process, which is tightly
coupled to cellular growth and proliferation rates and
which occupies the cell transcription machinery to a large
extent. Accordingly, in rapidly growing mammalian cells,
rRNA synthesis accounts for 35%–60% of all RNA tran-
scription.7,8 Transcription of rDNA is mediated by Pol I to
produce the 45S rRNA precursor of the 28S, 5.8S, and 18S
rRNA components of the ribosome.9 Two transcription fac-
tors have been defined for Pol I in mammals: one is the
selectivity factor SL1, which consists of the TATA-binding
protein (TBP) and three TBP-associated factors (TAFs),
and plays a critical role in recognition of the core promoter
element, and the other is the UBF, which interacts with the
upstream control element to facilitate the assembly of the
transcription initiation complex including SL1 and Pol I.10
UBF belongs to the sequence nonspecific class of HMG
(highmobility group) proteins. It has six HMG-box homol-
ogy domains and has been proposed to interact with rDNA
as a dimer and to induce six in-phase bends to generate a
Figure 1. Affected Individual 2 at Age 1
Year (A), 6 Years (B), and 10 Years (C)
single 360-loop structure that resem-
bles the nucleosome. Glu210 is part
of the second HMG-box homology
domain and is conserved in all species
which have UBTF. Because of the
similarity of the clinical phenotype
among the affected individuals, the
rarity of this variant and its de novo recurrence, we assumed
this is the disease-causing variant. Glu210 is followed by
two lysine residues (211 and 212), therefore p.Glu210Lys
variant would result in a string of three lysine residues.
Such a highly positive charge regionmay lead to a stronger
interaction with negatively charged DNA, conferring gain
of function to the protein.
We first studied the levels of UBF, Ser388 phosphorylated
UBF, as well as other Pol I-related components, including
POLR1E, TAF1A, and TAF1C, in fibroblasts of affected indi-
vidual 6 and a healthy control. Fibroblasts from passage
3–4 were grown in RPMI media with 10% FBS and 2 mM
Glutamine and the antibodies used for western blots
were UBF (Santa Cruz Biotechnology sc-13125), phos-
pho-UBF Ser388 (Santa Cruz Biotechnology sc-21637),
PolR1E (Santa Cruz Biotechnology sc-398270), TAF1C
(Santa Cruz Biotechnology sc-367333), TAF1A (Santa
Cruz Biotechnology sc-6572), and actin (Genetex
gt5512). This experiment revealed that all proteins were
present in the affected individual cells in a comparable
abundance to those of the control cells (Figure 3A). Next,
we investigated the transcription factor activity of UBF
on rDNA. To this end, we studied UBF binding to rDNA
promoters using chromatin immunoprecipitation (ChIP)-
qPCR as previously described.11 Briefly, cells were cross-
linked with 1% formaldehyde, and lysed in buffer con-
taining 1% SDS. The lysate was sonicated and incubated
overnight with 5 mg of UBF antibody (Santa Cruz Biotech-
nology sc-13125) and Protein A/G Sepharose (Santa Cruz
Biotechnology). Following elution, DNA was purified us-
ing a PCR purification kit (Omega Bio-Tek) and subjected
to real-time qPCR with PerfeCTa SYBR Green SuperMix
(Quanta), using a CFX Connect Real-Time Cycler (BioRad).
Previously described primers10 for rDNA Promoter (for:
CCCGGGGGAGGTATATCTTT; rev: ACAGGTCGCCAGAG
GACAG, rDNA ETS region (for: GAACGGTGGTGTGTCG
TTC; rev: CGTCTCGTCTCGTCTCACTC), and rDNA NTS
region (for: GATGGGTTTCGGGGTTCTAT; rev: GGCAGG
CAAATGTAGAAGG) were used.
It was already shown thatUBF binds strongly to rDNApro-
moter,weakly to the50-ETS (external transcribed spacer), and
does not bind at all to the NTS (non-transcribed spacer)10
(Figure 3B). In agreement, the ChIP-qPCR experiments re-
vealed a significantly increased binding (about X3) of UBF
to the rDNA promoter and ETS regions in the affected
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individual cells compared to control cells (Figure 3C). UBF
binding to the NTS control region in the affected individual
cells was comparable to that in the control cells.
Because of the increased binding of UBF to the rDNA pro-
moter in the affected individual cells, we next verified that
the expression of rDNA is increased in these cells by quan-
tifying 18S expression by real-time qPCR. Total mRNA
was purified from affected individual and control cells us-
ing TRIzol reagent (Invitrogen) according to the manufac-
turer’s instructions, and subjected to reverse transcription
using the RevertAid Reverse Transcriptase Kit (Thermo
Fisher Scientific) with oligo dT primers. Real-time qPCR
was performed as described above. The cDNA of GAPDH
was obtained and analyzed in parallel for normalization.
Primers used were: 18S set 1 (as in12) (for: GAAACTGCGA
ATGGCTCATTAAA; rev: CCACAGTTATCCAAGTAGGAGA
GGA); 18S set 2 13 (for: TTCGAACGTCTGCCCTATCAA;
rev: ATGGTAGGCACGGCGACTA); and GAPDH (for:
TGCACCACCAACTGCTTAGC; rev: GGCATGGACTGTG
GTCATGAG). This analysis showed that the 18S expres-
sion was about four-fold higher in the affected individual
cells compared to control cells (Figure 3D). These results
confirm that the UBF which carries the p.Glu210Lys
variant functions as a hyperactive transcription factor,
resulting in increased expression of rDNA.
The rDNA locus occupies a distinctive region of the
genome and is located in the nucleolus, where its tran-
scription is coupled to ribosomal biogenesis.14 Increased
rDNA expression is associated with chromatin deconden-
sation at the rDNA locus and enlarged nucleoli.15,16 We
therefore checked whether the mutant UBF affects nucle-
olar architecture. Cells of an affected individual and con-
trol were methanol-fixed and subjected to immunofluores-
cence staining using antibodies recognizing the nucleolar
marker nucleolin (Abcam ab50279). In line with the
increased rDNA expression, we observed that the affected
individual cells showed increased nucleolar size (Figures
3E and 3F). Interestingly, this was coupled with a reduction
Figure 2. Progressive Cortical Atrophy Observed in Serial Brain MRI
(A–C) Parasagittal T1-weighted brainMRI of affected individual 3 at age 4, 9, and 11 years, respectively. Note progressive cortical atrophy
with slight cerebellar atrophy.
(D and E) Axial and Midsagittal T1 images of affected individual 4 at age 15 years. Note cortical and cerebellar atrophy.
(F) Axial T2 of affected individual 6 at age 8 years. Note cortical atrophy and periventricular white matter hyperintensity (arrows).
(G and H) T2 weighted axial and sagittal sequences. Early imaging on affected individual 2 showing modest ventricular dilatation
ex-vacuo associated with a thin corpus callous (arrows).
(I and J) T2 Weighted axial and sagittal FLAIR sequences in a follow up imaging study repeated after 6 years showing dramatic cortical
atrophy and ex-vacuo ventricular dilatation. Note is made of the subdural hygroma below the tentorium in (J).
270 The American Journal of Human Genetics 101, 267–273, August 3, 2017
in the overall number of nucleoli per cell (Figures 3E and
3G). This reorganization of the nucleolar material is sug-
gestive of altered rDNA chromatin status.
Alteration of UBF level was already shown to propagate
detrimental effect. Depletion of UBF was shown to silence
rDNA and its total ablation is likely incompatible with
life.17,18 In agreement, UBTF is highly intolerant to both
deleterious and missense variants; in the ExAC cohort,
the number of UBTF variants markedly deviate from the
expected by its length (Z ¼ 5.61) with expected/observed
number of missense variants 295/98 and of loss-of-func-
tion (LOF) variants 36/0.
Overexpression of UBTF in neonatal rat cardiomyocytes
led to a proportional increase in rDNA transcription.19 In
agreement, we demonstrate that the increased binding
of UBF to the rDNA promoter is associated with a similar
increase in 18 s rRNA level. Markedly elevated, normal
rRNA transcripts, seems a unique phenomenon and several
consequences could be envisioned, including scavenging
of RNA binding proteins, scavenging of RNA disposal ma-
chinery, or altered ribosome biogenesis. It is of note that
the expression of rRNA and ribosomal proteins is tightly
co-regulated in response to growth and stress signals.20
Uncoupled overexpression of bacterial rDNA results in
increased free ribosomal subunits with marked dominant
negative effect.21 The effect of excessive rRNA on neural
tissue could be deleterious and might even culminate in
neurodegeneration; in adult rat hippocampal neurons,
Figure 3. Mutant UBF Is Hyperactive and Drives Increased Expression of rDNA Genes, Associated with Nucleolar Alterations
(A) Western blot analysis of cells of control and affected individual showing that the UBTF mutation does not affect UBF steady state
levels, its phosphorylation status, or the levels of the Pol I subunits PolR1E, TAF1A, and TAFC.
(B) Schematic representation of the rDNA gene locus, indicating the location of each primer set used: Promoter, external transcribed
spacer (ETS), and non-transcribed spacer (NTS).
(C) UBF ChIP-qPCR showing that UBF binding to the Promoter and ETS region is significantly increased in cells of the affected individual
compared to control cells. Binding was quantified relative to input material, and shown as normalized to the NTS locus in control cells.
Bars represent the average of three independent experiments, and error bars represent SD. The asterisk indicates statistical significance
(p < 0.05) evaluated using the t test (two-tailed, equal variance).
(D) Quantification of 18S expression in cells of affected individual and control, using real-time qPCR, quantified relative to GAPDH
expression. Two different 18S primer sets were used. The results are shown as normalized to control cells. Bars represent the average
of three independent experiments, and error bars represent SD. The asterisk indicates statistical significance (p < 0.05) evaluated using
the t test (two-tailed, equal variance).
(E) Representative micrographs of anti-nucleolin immunofluorescence showing altered nucloelar pattern in affected individual cells.
(F) Quantification of nucleolar size. Nucleolar area was quantified using ImageJ and statistical analysis was done with Prism (t test,
two-tailed, equal variance). Asterisks indicate statistical significance (p < 0.0001). The mean5 SEM is also shown.
(G) Quantification of the number of nucleoli in each cell (117 control and 151 affected individual cells were analyzed).
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enhanced Pol I activation promoted neurite outgrowth,
including abnormally increased total neurite length and
branching,22 which in itself was shown to precede neuro-
degeneration.23
Cell mitosis and DNA damage repair could also be
affected by excessive transcription of rDNA due to deple-
tion of untranscribed rDNA. Untranscribed rDNA serve
as binding sites for condensin,24 which is required for
DNA damage repair and chromatid cohesion.25 Impaired
binding of condensin to untranscribed rDNA is associated
with premature sister chromatids separation, before dam-
age repair is completed.26
Finally, UBF is an important regulator of chromatin
structure at the rDNA locus; it was shown to outcompete
linker Histone H1 resulting in decondensation of rDNA
chromatin.17 Changes in chromatin status at the rDNA lo-
cus, coupled with nucleolar alterations, have been previ-
ously reported in Huntington disease [MIM 143100]16
and were regulated by UBF post-translational modification
by acetylation at Lys-352 and methylation at Lys-232.16,27
The abnormally increased nucleolar size and reduced
number of nucleoli per cell which was observed in the
cells of the affected individual, suggest that the mutant
hyperactive UBF causes an alteration in rDNA chromatin
structure. Such a dysregulation would have a profound
impact, since rDNA heterochromatin status is tightly regu-
lated during differentiation and has a broader effect on
heterochromatin formation throughout the nucleus.17,28
Obviously, the data and the consequent assumptions
should be regarded as preliminary, because all derived
from a single cell line of an affected individual and one
healthy control.
In summary, in seven individuals with developmental
regression and neurodegeneration in childhood, we identi-
fied the heterozygous c.628G>A variant inUBTF. In cells of
an affected individual, the variant conferred gain of func-
tion to UBF with the subsequent production of markedly
increased amount of rRNA and alteration of nucleoli size
and number. This report links neuronal degeneration in
childhood with aberrant rRNA metabolism.
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